Skip to content

S. Parker Singleton

8 papers in the library · 195 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression

Nature Mental Health May 1, 2026 S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey et al. 2 citations

This study presents a living systematic review and open-data meta-analytic database from 15 randomized controlled trials examining the effects of psilocybin treatment on depressive symptoms. Existing evidence suggests that psilocybin treatment alleviates depressive symptoms. Depression is a major cause of disability worldwide, motivating interest in psilocybin as a potential treatment. Here we...

A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD

medRxiv Preprint Server March 27, 2026 Brooke L. Sevchik, S. Parker Singleton, Analiese Lahey et al. preprint

3,4-methylenedioxymethamphetamine (MDMA) has emerged as a potential treatment for post-traumatic stress disorder (PTSD), generating considerable enthusiasm in the field. However, rapidly changing evidence in a fast-moving field can be challenging to integrate. Here, we present a living systematic review and open-data meta-analytic resource on MDMA treatment for PTSD. In this initial release,...

Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin

Molecular Psychiatry February 3, 2026 Pablo Mallaroni, S. Parker Singleton, Natasha L. Mason et al.

As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored for specific populations. 2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenethylamine reported to produce less dysphoria and subjective impairment than the psychedelic tryptamine psilocybin. Despite its popularity among recreational...

Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource

medRxiv August 16, 2025 S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey et al. preprint

Abstract Importance Depression is a major cause of disability worldwide, motivating substantial interest in psilocybin as a potential treatment. Objective To conduct a systematic review and meta-analysis of psilocybin’s impact on depressive symptoms and provide a living open data resource. Data Sources PubMed, Embase, Scopus, Web of Science, and PsycINFO retrieved by a systematic search up to...

Network control energy reductions under DMT relate to serotonin receptors, signal diversity, and subjective experience.

Communications Biology April 18, 2025 S Parker Singleton, Christopher Timmermann, Andrea I. Luppi et al. 17 citations

Psychedelics offer a profound window into the human brain through their robust effects on perception, subjective experience, and brain activity patterns. The serotonergic psychedelic N,N-dimethyltryptamine (DMT) induces a profoundly immersive altered state of consciousness lasting under 20 min, allowing the entire experience to be captured during a single functional magnetic resonance imaging...

The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin

bioRxiv (Cold Spring Harbor Laboratory) October 22, 2024 Pablo Mallaroni, S. Parker Singleton, Natasha L. Mason et al. 2 citations preprint

As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored for specific populations. 2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenethylamine reported to produce less dysphoria and subjective impairment than the psychedelic tryptamine psilocybin. Despite its popularity among recreational...

Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience

bioRxiv (Cold Spring Harbor Laboratory) May 12, 2023 S. Parker Singleton, Christopher Timmermann, Andrea I. Luppi et al. 18 citations preprint

Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, subjective experience, and brain activity patterns. In recent work using a receptor-informed network control theory framework, we demonstrated that the serotonergic psychedelics lysergic acid diethylamide (LSD) and psilocybin flatten the brain's control energy...

Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape.

Nature Communications October 3, 2022 S Parker Singleton, Andrea I. Luppi, Robin Carhart-Harris et al. 156 citations

Psychedelics including lysergic acid diethylamide (LSD) and psilocybin temporarily alter subjective experience through their neurochemical effects. Serotonin 2a (5-HT2a) receptor agonism by these compounds is associated with more diverse (entropic) brain activity. We postulate that this increase in entropy may arise in part from a flattening of the brain's control energy landscape, which can be...